I've spent a lot of time on this site talking about GLP-1 receptor agonists — and for good reason. Tirzepatide, retatrutide, semaglutide — the clinical data behind these compounds has been genuinely extraordinary. But there's another satiety hormone that most people haven't heard of, and the research community has been quietly building a case that it might be the missing piece in metabolic medicine.
That hormone is amylin. And when you combine an amylin analogue with a GLP-1 agonist — which is exactly what CagriSema does — the weight loss data goes places we haven't seen before.
CagriSema pairs cagrilintide, a long-acting amylin analogue, with semaglutide, targeting two distinct satiety pathways in a single weekly injection. The REDEFINE 1 trial showed roughly 23% total body weight loss at 68 weeks, meaningfully exceeding semaglutide alone. This is not just "more GLP-1" — amylin acts through genuinely different brain regions, and the combination represents novel biology in weight management.
The satiety hormone you should know about
Amylin is a 37-amino acid peptide hormone that is co-secreted with insulin from the beta cells of your pancreas after meals. Every time you eat and your pancreas releases insulin, it simultaneously releases amylin. This co-secretion is not coincidental — amylin and insulin work as a coordinated system to manage the postprandial metabolic response.
What amylin does is elegant: it slows gastric emptying, suppresses postprandial glucagon secretion, and — this is the key part — it signals satiety through the central nervous system. Amylin crosses the blood-brain barrier and binds to receptors in the area postrema and the lateral parabrachial nucleus, brain regions that process visceral signals related to fullness and meal termination.
Here's what makes this interesting in the context of GLP-1 therapies: GLP-1 and amylin reduce appetite through overlapping but distinct neural circuits. GLP-1 receptor agonists primarily act on the hypothalamic arcuate nucleus and brainstem nuclei — different anatomical targets from amylin's primary sites of action. They're both telling your brain "you've had enough," but they're sending that message through different phone lines.
This is a critical distinction. When two signals converge on the same outcome through independent pathways, the combined effect has the potential to be more than additive. It's the same principle behind combining GHRH with GHRP for growth hormone release — two different receptor systems amplifying a single biological response.
Why amylin biology matters for metabolic medicine
There's a detail about amylin that often gets overlooked: in people with type 2 diabetes, amylin secretion is impaired alongside insulin secretion. As beta cell function deteriorates, you lose both hormones. The metabolic dysfunction in type 2 diabetes isn't just about insulin — it's simultaneously about losing a key satiety signal.
Pramlintide (brand name Symlin) was actually the first amylin analogue approved for clinical use, way back in 2005, for use alongside insulin in diabetes management. But pramlintide required multiple daily injections and had a short duration of action, which limited its practical utility. The science was solid; the pharmacokinetics weren't ideal.
Cagrilintide is Novo Nordisk's long-acting amylin analogue. It has a significantly extended half-life compared to pramlintide, allowing for once-weekly dosing. As a standalone compound, cagrilintide showed approximately 10-11% body weight reduction over 26 weeks in Phase 2 data. That's impressive for a single agent, but it was the combination data that really turned heads.
The combination approach
CagriSema is a fixed-ratio co-formulation of cagrilintide and semaglutide 2.4mg (the same dose used in Wegovy). Take the most proven GLP-1 agonist and combine it with a long-acting amylin analogue in a single weekly injection.
The biological rationale is sound. Semaglutide activates GLP-1 receptors in the hypothalamus, reducing appetite through POMC/CART neuron activation and NPY/AgRP neuron inhibition. Cagrilintide activates amylin receptors in the area postrema and hindbrain, triggering a separate but complementary satiety cascade. Together, you're modulating appetite at multiple levels of the central nervous system simultaneously.
There's also a metabolic component beyond appetite. Amylin receptor activation has been shown to increase energy expenditure in preclinical models, potentially through brown adipose tissue activation. GLP-1 improves insulin sensitivity and reduces hepatic glucose output. The metabolic effects are complementary in ways that go beyond simply eating less.
The research community has referenced this combination formulation at standard clinical concentrations (ref: CS10), consistent with the dosing used across the REDEFINE trial program.
REDEFINE 1: the data that changed the conversation
The REDEFINE 1 trial was the Phase 3 study that put CagriSema on the map. It enrolled approximately 3,400 adults with obesity (BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity) but without type 2 diabetes. The trial ran for 68 weeks and compared CagriSema against semaglutide 2.4mg alone, cagrilintide alone, and placebo.
The headline: participants on CagriSema lost approximately 22.7% of their body weight at 68 weeks. The semaglutide-alone arm lost approximately 15.8%, and the cagrilintide-alone arm lost approximately 8.6%.
The absolute magnitude is striking. Roughly 23% body weight loss from a pharmacological intervention puts CagriSema in the same territory as the most effective metabolic interventions we have, approaching the range historically seen only with bariatric surgery.
Then there's the delta over semaglutide alone. CagriSema produced approximately 7 percentage points more weight loss than semaglutide 2.4mg, which is already one of the most effective weight loss agents ever studied. That incremental benefit — roughly 40-45% more weight loss than semaglutide alone — is directly attributable to the amylin pathway. This is not a minor add-on effect.
A meaningful proportion of CagriSema-treated participants achieved 25% or greater total body weight loss. In the GLP-1 field, we've learned that the proportion of "super-responders" is often more clinically relevant than the mean, because it tells you about the ceiling of what the compound can do when biology and adherence align.
The competitive landscape
This is a question I get asked constantly, so I want to lay it out clearly.
Semaglutide 2.4mg is a single GLP-1 agonist. The STEP 1 trial showed approximately 15-17% weight loss at 68 weeks. This is the current standard of care. CagriSema appears to add roughly 7 percentage points on top of this through the amylin pathway.
Tirzepatide is a dual GIP + GLP-1 agonist. The SURMOUNT-1 trial showed approximately 22.5% weight loss at 72 weeks with the highest dose — the current high-water mark among approved agents. CagriSema's numbers are in a similar range, but through a fundamentally different mechanism: amylin + GLP-1 rather than GIP + GLP-1.
Retatrutide is a triple GLP-1 + GIP + glucagon agonist. Phase 2 data showed approximately 24.2% weight loss at 48 weeks. Still in development, and the Phase 3 data will be important for head-to-head comparisons. Retatrutide's glucagon component adds an energy expenditure mechanism that neither tirzepatide nor CagriSema directly replicate.
What's fascinating is that each of these compounds achieves similar magnitudes of weight loss through different mechanistic routes. Tirzepatide adds GIP. Retatrutide adds glucagon. CagriSema adds amylin. The convergence of outcomes despite divergent mechanisms tells us something important: the body has multiple redundant systems for regulating energy balance, and targeting more than one of them produces better results than targeting any single pathway.
Cagrilintide as a standalone
Before CagriSema, cagrilintide was studied as a standalone agent, and those results are worth understanding because they isolate the amylin effect.
A Phase 2 trial published in The Lancet evaluated cagrilintide at multiple doses in adults with overweight or obesity. At the highest dose over 26 weeks, participants lost approximately 10.8% of body weight — significantly more than placebo. The dose-response curve was clear and the safety profile was manageable, with gastrointestinal side effects being the most common.
What this data tells us about amylin as a weight loss mechanism is significant. A 10-11% weight loss from a single amylin analogue — without any GLP-1 component — demonstrates that amylin signaling is a legitimate, independent pathway for appetite regulation. This isn't just riding on the coattails of GLP-1 science. Amylin has its own story.
The standalone data also suggests that the additional weight loss seen with CagriSema versus semaglutide alone is genuinely attributable to the amylin mechanism, not some pharmacokinetic interaction or formulation artifact. Two pathways, each with independent efficacy, combined for an enhanced result.
The Novo Nordisk pipeline context
CagriSema deserves to be understood in the broader context of what's happening in metabolic medicine development, because the competitive landscape is relevant.
Novo Nordisk has been the dominant force in GLP-1 therapeutics — they developed liraglutide and semaglutide, which essentially created the modern obesity pharmacotherapy field. But Eli Lilly's tirzepatide caught them somewhat off guard with its dual-agonist approach. CagriSema is, in part, Novo Nordisk's strategic response: rather than adding GIP (Lilly's approach), they're adding amylin.
The REDEFINE clinical trial program includes REDEFINE 1 (obesity without diabetes), REDEFINE 2 (obesity with type 2 diabetes), REDEFINE 3 (head-to-head against tirzepatide), and REDEFINE 4 (obesity with heart failure). The breadth of this program signals that Novo Nordisk views CagriSema as their flagship next-generation compound.
REDEFINE 2 is particularly interesting because amylin biology is especially relevant in diabetes — where endogenous amylin is depleted alongside insulin. Restoring amylin signaling in a population that's specifically deficient in it has strong biological logic.
REDEFINE 3 — the head-to-head against tirzepatide — will be the most watched trial in metabolic medicine. It will directly answer whether amylin + GLP-1 produces better outcomes than GIP + GLP-1. Different mechanism, same question: which combination of satiety pathways produces the best results?
What makes this genuinely different
I want to address this directly because it's a fair question. The metabolic medicine space has seen a wave of GLP-1-based compounds, and there's a reasonable skepticism about whether each new entry is genuinely different or just incrementally tweaked.
CagriSema is genuinely different.
The amylin pathway is not a variation of GLP-1 signaling — it's a separate endocrine system. Amylin receptors are calcitonin receptors complexed with receptor activity-modifying proteins (RAMPs). They have a completely different molecular structure from GLP-1 receptors. They're expressed in different brain regions. They activate different intracellular signaling cascades.
When I look at the metabolic medicine landscape, I see three distinct pharmacological strategies emerging: the incretin approach (GLP-1 and GIP), the glucagon approach (energy expenditure via hepatic fat oxidation), and the amylin approach (hindbrain satiety and postprandial regulation). The most effective therapies of the next decade will likely combine elements from two or more of these strategies.
CagriSema represents the first clinical validation of the incretin + amylin combination. Whether it will ultimately prove superior to the incretin + glucagon combination (retatrutide) or the dual incretin approach (tirzepatide) is an open question that the REDEFINE program should help answer.
Regulatory timeline and practical considerations
Novo Nordisk submitted CagriSema for regulatory review based on the REDEFINE 1 data, with approvals anticipated in major markets through 2026-2027. The regulatory path has been relatively straightforward because both components — semaglutide and cagrilintide — have well-characterized safety profiles individually.
The gastrointestinal side effect profile appears generally consistent with what we'd expect from GLP-1 therapy: nausea, vomiting, and diarrhea, primarily during dose escalation. The combination doesn't appear to dramatically worsen GI tolerability compared to semaglutide alone, which is an important practical consideration. Amylin's gastric emptying effects are mechanistically similar to GLP-1's, so the overlap in side effects is expected.
The once-weekly injection format mirrors existing semaglutide dosing, which should ease the practical adoption curve for clinicians and patients already familiar with the GLP-1 agonist class.
Why dual-pathway approaches keep winning
Here's what I keep coming back to when I look at the metabolic medicine data over the past five years: every time researchers have combined two distinct satiety or metabolic pathways, the results have exceeded single-pathway approaches. Tirzepatide beat semaglutide. Retatrutide's triple agonism showed the fastest weight loss kinetics we've seen. And now CagriSema has added roughly 7 percentage points to semaglutide through amylin.
The pattern is consistent and the biological logic is clear. Obesity is a condition maintained by multiple redundant regulatory systems. Targeting one pathway produces meaningful results. Targeting two or three pathways produces dramatically better results because you're addressing the redundancy that evolution built into energy balance regulation.
I think we're heading toward a future where the metabolic compound landscape is defined not by single agents but by combinations — and the research question becomes which combinations of pathways produce the optimal balance of efficacy, safety, and tolerability for different patient populations.
CagriSema is a major data point in that conversation. The amylin pathway is real, it's clinically validated, and the combination with GLP-1 produces results that matter. Whether it's the best combination remains to be seen — but the REDEFINE program is designed to answer exactly that question.
Frequently asked questions
What exactly is CagriSema?
CagriSema is a combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) in a single once-weekly injection. It targets two distinct satiety pathways — amylin receptors in the hindbrain and GLP-1 receptors in the hypothalamus — rather than relying on GLP-1 signaling alone. This dual-pathway approach produced approximately 23% weight loss in the REDEFINE 1 trial, exceeding what semaglutide achieved as a single agent.
Why should I care about amylin?
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells after meals. It promotes satiety by acting on receptors in the area postrema and lateral parabrachial nucleus, slows gastric emptying, and suppresses postprandial glucagon. It represents a satiety pathway independent from GLP-1, meaning it can reduce appetite through mechanisms that GLP-1 alone doesn't fully engage. In people with type 2 diabetes, amylin secretion is impaired, making its replacement especially relevant.
How does it stack up against tirzepatide and retatrutide?
CagriSema, tirzepatide, and retatrutide all produce roughly similar magnitudes of weight loss (approximately 22-25%) but through different mechanistic approaches. Tirzepatide combines GIP and GLP-1. Retatrutide adds glucagon for a triple agonist approach. CagriSema combines amylin with GLP-1. The head-to-head REDEFINE 3 trial comparing CagriSema directly against tirzepatide will be essential for sorting out relative efficacy.
What did REDEFINE 1 actually show?
REDEFINE 1 enrolled approximately 3,400 adults with obesity and found that CagriSema produced approximately 22.7% body weight loss at 68 weeks, compared to 15.8% for semaglutide alone, 8.6% for cagrilintide alone, and 2.3% for placebo. The safety profile was generally consistent with existing GLP-1 therapies, with gastrointestinal symptoms being the most common side effects.
Can I get CagriSema now?
CagriSema is in the regulatory review process, with approvals anticipated in major markets through 2026-2027. Novo Nordisk has submitted regulatory filings based on the REDEFINE 1 data, with additional trials (REDEFINE 2, 3, and 4) studying the combination in diabetes, head-to-head comparisons, and heart failure populations.
Will CagriSema fix the weight regain problem?
This is one of the most important open questions in metabolic medicine. Current data on GLP-1 monotherapy suggests that weight tends to return after discontinuation. Whether CagriSema's dual-pathway approach provides more durable weight maintenance is not yet established — this will require longer-term data beyond the initial 68-week trial period. The biological hypothesis is that engaging more satiety pathways could lead to a more sustained metabolic reset, but this remains to be demonstrated.